123 related articles for article (PubMed ID: 36762693)
21. Network pharmacological evaluation of
Pahal S; Gupta A; Choudhary P; Chaudhary A; Singh S
J Biomol Struct Dyn; 2022; 40(21):10887-10898. PubMed ID: 34278961
[TBL] [Abstract][Full Text] [Related]
22. Identification of bioactive molecule from
Tripathi MK; Singh P; Sharma S; Singh TP; Ethayathulla AS; Kaur P
J Biomol Struct Dyn; 2021 Sep; 39(15):5668-5681. PubMed ID: 32643552
[TBL] [Abstract][Full Text] [Related]
23. Linking High-Throughput Screens to Identify MoAs and Novel Inhibitors of Mycobacterium tuberculosis Dihydrofolate Reductase.
Santa Maria JP; Park Y; Yang L; Murgolo N; Altman MD; Zuck P; Adam G; Chamberlin C; Saradjian P; Dandliker P; Boshoff HIM; Barry CE; Garlisi C; Olsen DB; Young K; Glick M; Nickbarg E; Kutchukian PS
ACS Chem Biol; 2017 Sep; 12(9):2448-2456. PubMed ID: 28806050
[TBL] [Abstract][Full Text] [Related]
24. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
El-Hamamsy MH; Smith AW; Thompson AS; Threadgill MD
Bioorg Med Chem; 2007 Jul; 15(13):4552-76. PubMed ID: 17451962
[TBL] [Abstract][Full Text] [Related]
25. Screening of indole derivatives as the potent anticancer agents on dihydrofolate reductase: pharmaco-informatics and molecular dynamics simulation.
Abdolmaleki B; Maddah M
J Biomol Struct Dyn; 2023 May; 41(8):3667-3679. PubMed ID: 35318890
[TBL] [Abstract][Full Text] [Related]
26. Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs.
Dias MV; Tyrakis P; Domingues RR; Paes Leme AF; Blundell TL
Structure; 2014 Jan; 22(1):94-103. PubMed ID: 24210757
[TBL] [Abstract][Full Text] [Related]
27. Dihydrofolate reductase inhibitors for use as antimicrobial agents.
He J; Qiao W; An Q; Yang T; Luo Y
Eur J Med Chem; 2020 Jun; 195():112268. PubMed ID: 32298876
[TBL] [Abstract][Full Text] [Related]
28. Synthesis,
Gaurav I; Singh T; Thakur A; Kumar G; Rathee P; Kumari P; Sweta K
Curr Pharm Biotechnol; 2020; 21(15):1674-1687. PubMed ID: 32614743
[TBL] [Abstract][Full Text] [Related]
29. Dihydrofolate reductase and cell growth activity inhibition by the beta-carboline-benzoquinolizidine plant alkaloid deoxytubulosine from Alangium lamarckii: its potential as an antimicrobial and anticancer agent.
Rao KN; Venkatachalam SR
Bioorg Med Chem; 1999 Jun; 7(6):1105-10. PubMed ID: 10428380
[TBL] [Abstract][Full Text] [Related]
30. 3D-QSAR, molecular docking, DFT and ADMET studies on quinazoline derivatives to explore novel DHFR inhibitors.
Hadni H; Bakhouch M; Elhallaoui M
J Biomol Struct Dyn; 2023 Jan; 41(1):161-175. PubMed ID: 34825630
[TBL] [Abstract][Full Text] [Related]
31. Modulation of GPCR receptors common to gut inflammatory diseases and neuronal disorders, Alzheimer's and Parkinson's diseases as druggable targets through
Shukla R; Pahal S; Gupta A; Choudhary P; Misra K; Singh S
J Biomol Struct Dyn; 2023 Jul; 41(10):4485-4503. PubMed ID: 35491707
[TBL] [Abstract][Full Text] [Related]
32. Identification of selective
Sharma VK; Kathuria D; Bharatam PV
J Biomol Struct Dyn; 2022; 40(19):8687-8695. PubMed ID: 33904374
[TBL] [Abstract][Full Text] [Related]
33. The structure and competitive substrate inhibition of dihydrofolate reductase from Enterococcus faecalis reveal restrictions to cofactor docking.
Bourne CR; Wakeham N; Webb N; Nammalwar B; Bunce RA; Berlin KD; Barrow WW
Biochemistry; 2014 Feb; 53(7):1228-38. PubMed ID: 24495113
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel DHFR inhibitors for treatment of tuberculosis by combining virtual screening with in vitro activity assay.
Wang N; Ren JX; Xie Y
J Biomol Struct Dyn; 2019 Mar; 37(4):1054-1061. PubMed ID: 29504455
[No Abstract] [Full Text] [Related]
35. Multicomplex-based pharmacophore modeling in conjunction with multi-target docking and molecular dynamics simulations for the identification of
Manhas A; Lone MY; Jha PC
J Biomol Struct Dyn; 2019 Oct; 37(16):4181-4199. PubMed ID: 30648473
[No Abstract] [Full Text] [Related]
36. Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine: the in vitro cytotoxicity of these plant alkaloids and their potential as antimicrobial and anticancer agents.
Rao KN; Venkatachalam SR
Toxicol In Vitro; 2000 Feb; 14(1):53-9. PubMed ID: 10699361
[TBL] [Abstract][Full Text] [Related]
37. Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001-2021).
Bhagat K; Kumar N; Kaur Gulati H; Sharma A; Kaur A; Singh JV; Singh H; Bedi PMS
Expert Opin Ther Pat; 2022 Oct; 32(10):1079-1095. PubMed ID: 36189616
[TBL] [Abstract][Full Text] [Related]
38. Halogenated derivatives of methotrexate as human dihydrofolate reductase inhibitors in cancer chemotherapy.
Uddin N; Ahmed S; Khan AM; Mazharol Hoque M; Halim MA
J Biomol Struct Dyn; 2020 Feb; 38(3):901-917. PubMed ID: 30938661
[TBL] [Abstract][Full Text] [Related]
39. Analysis of medicinal and therapeutic potential of
Gheshlaghi SZ; Nakhaei E; Ebrahimi A; Jafari M; Shahraki A; Rezazadeh S; Saberinasab E; Nowroozi A; Hosseini SS
J Biomol Struct Dyn; 2023; 41(14):6883-6893. PubMed ID: 35993530
[TBL] [Abstract][Full Text] [Related]
40. Virtual screening, docking, and dynamics of potential new inhibitors of dihydrofolate reductase from Yersinia pestis.
Bastos Lda C; de Souza FR; Guimarães AP; Sirouspour M; Cuya Guizado TR; Forgione P; Ramalho TC; França TC
J Biomol Struct Dyn; 2016 Oct; 34(10):2184-98. PubMed ID: 26494420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
